Certificate published for every lotSame-day dispatch before 1pm, Monday to FridayFree Royal Mail Tracked 48 over £100
ALTAResearch peptides
Coming soonCT-G32 research compound vial, coming soon
FormatTo be confirmed
AreaWeight & Metabolic
StatusComing soon
Weight & Metabolic · Research compoundComing soon

CT-G32 (SCO-940)

GLP-1 / GIP / glucagon / amylin quadruple agonist

Lot certificate published at release

Celltrion and SCOHIA PHARMA's quadruple agonist: one molecule designed to activate the GLP-1, GIP, glucagon and amylin receptors. Price and availability coming soon; register to hear first.

Coming soonPrice and vial size to be announced
Email me when CT-G32 is available, plus new lots and offers. Unsubscribe any time. Privacy
  • Price and release date posted here first
  • Lot certificate published before it goes on sale
  • Royal Mail Tracked 48, free over £100, plain packaging
In stock now: retatrutideThe GLP-1 / GIP / glucagon triple agonist CT-G32 was compared against →
§ 01

Specification

Data sheet · provisional
Name
CT-G32 (Celltrion) / SCO-940 (SCOHIA PHARMA)
Class
Quadruple receptor agonist (peptide-based)
Targets
GLP-1, GIP, glucagon and amylin receptors
Developers
Celltrion (Incheon, South Korea) with SCOHIA PHARMA (Fujisawa, Japan)
Development stage
Preclinical: rat and monkey studies; first human trial planned for Q2 2027
Sequence
Not yet published by the developers
Format
To be confirmed, with the lot certificate, at release
Price
Coming soon
§ 02

About CT-G32

What CT-G32 is

CT-G32, also coded SCO-940, is an experimental obesity and metabolic compound from Celltrion and Japan's SCOHIA PHARMA. It is a single molecule designed to switch on four hormone receptors at once: GLP-1, GIP, glucagon and amylin. Semaglutide acts on one of these, tirzepatide on two and retatrutide on three; CT-G32 is the first disclosed molecule built to act on all four.

What the first data showed

The first results were presented at TIDES Europe in Amsterdam in November 2026, and all of them are from animals. In diet-induced obese rats, CT-G32 produced numerically greater weight loss than retatrutide at the same molar dose, with a smaller share of the weight lost coming from lean mass, and it lowered obesity-related high insulin. In monkeys it stayed in the blood long enough to support a once-weekly profile. The companies have not yet published the percentages or the amino-acid sequence. Our CT-G32 explainer covers the results, the timeline and what they do not show.

Availability

CT-G32 is coming soon to ALTA PEPTIDES. Price, vial size and release date will be confirmed here, together with the certificate of analysis for the first lot, before it goes on sale. Register below to be told first. Celltrion plans to ask the US FDA to begin human trials by February 2027; CT-G32 is not a licensed medicine anywhere, including the UK.

How identity will be shown

Every ALTA PEPTIDES compound ships against a published lot certificate. For CT-G32 that means identity by mass spectrometry and purity by HPLC, set against the structure once the developers publish it. Until then, treat any listing that claims a verified CT-G32 sequence with caution. Our guide to reading a certificate of analysis explains what to check.

Researching in the meantime

The closest compound with a large body of published research is retatrutide, the GLP-1, GIP and glucagon triple agonist that CT-G32 was compared against in rats. ALTA PEPTIDES holds retatrutide research vials and the sealed retatrutide pen in UK stock, each with a published lot certificate. For the wider field, see our guides to amylin agonists and retatrutide.

For laboratory research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a medicine or a supplement. Sold to researchers aged 18 and over. Nothing on this page is a recommendation for any use of this compound.
§ 03

Questions

When will CT-G32 be available?
CT-G32 is coming soon to ALTA PEPTIDES. Price, vial size and release date will be posted on this page, with the lot certificate, before it goes on sale. Register your email above to be told first.
How much will CT-G32 cost?
The price is not set yet. It will be published here before release, alongside the price per milligram so it can be compared with retatrutide.
What is CT-G32?
An experimental quadruple agonist from Celltrion and SCOHIA PHARMA, also coded SCO-940. One molecule designed to activate the GLP-1, GIP, glucagon and amylin receptors. It has been tested in rats and monkeys only.
Is CT-G32 the same as SCO-940?
Yes. CT-G32 is Celltrion's code and SCO-940 is SCOHIA PHARMA's code for the same molecule. It is also searched as CTG32 or CT G32.
Is CT-G32 approved in the UK?
No. CT-G32 is not a licensed medicine anywhere. Its first human trial is planned for the second quarter of 2027. Anything sold under the name is a research compound for laboratory use only.
How does CT-G32 compare with retatrutide?
In obese rats it produced more weight loss than retatrutide at the same molar dose, with less lean mass lost. That is one animal study; retatrutide has five completed phase 3 trials in people, and CT-G32 has none yet.
Is CT-G32 a quadruple GLP-1 agonist?
In the loose sense the phrase is used, yes. CT-G32 is a quadruple agonist: GLP-1, GIP, glucagon and amylin receptors are all targets of the one molecule, which is why it is also described as a GLP quadruple agonist. GLP-1 is only one of the four: semaglutide acts on that receptor alone, tirzepatide on two and retatrutide on three.
§ 04

In stock now

See all →
Retatrutide Pen pre-filled penNewNo. 014
Weight & MetabolicPen

Retatrutide Pen

Synedica pre-filled pen: 40 mg retatrutide, with needles

Size
40 mg pen
HPLC
99.752%
Lot
07022601
£139.99£3.50/mg